Volume 29, Issue 2 (June 2025)                   Physiol Pharmacol 2025, 29(2): 106-110 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karsono A H, Setiawan L T K, Tjandrawinata R R. Genotoxicity test study of bioactive protein fraction from Lumbricus rubellus, DLBS1033. Physiol Pharmacol 2025; 29 (2) :106-110
URL: http://ppj.phypha.ir/article-1-2298-en.html
Genotoxicity test study of bioactive protein fraction from Lumbricus rubellus, DLBS1033
Agung Heru Karsono , Lidwina Tri Kristanti Setiawan , Raymond Rubianto Tjandrawinata
Abstract:   (1070 Views)

Introduction: Genotoxicity is one of the safety concerns that can lead to damage at the genetic level. The observation of DLBS1033 using AMES and micronucleus tests was conducted to ensure the safety precautions.
Methods: Ames test was done using 3 strains of Salmonella typhimurium (TA98, TA100, and TA1535) with or without metabolic activation (S9 enzyme). In vitro micronucleus test was performed with prolonged exposure without S9. The variation of DLBS1033 concentrations were 100, 600, and 1200 µg/ml.
Results: The results of the Ames test (with/without S9) and in vitro micronucleus (prolonged exposure without S9) showed that DLBS1033 did not have a mutagenic effect.
Conclusion: DLBS1033 was safe and did not show any genotoxic activity.

Keywords: Ames test, Genotoxicity, Lumbricus rubellus, Micronucleus test
Full-Text [PDF 285 kb]   (64 Downloads)    
Type of Manuscript: Short communication | Subject: Toxicology
References
1. Agoncillo A. Meta-analysis on the safety and efficacy of Lumbrokinase in peripheral arterial disease. Eur Heart J Acute Cardiovasc Care. 2021;10(Suppl 1). [DOI:10.1093/ehjacc/zuab020.219]
2. Biran A, Yagur-Kroll S, Pedahzur R, et al. Bacterial genotoxicity bioreporters. Microb Biotechnol 2010; 3: 412-427. [DOI:10.1111/j.1751-7915.2009.00160.x]
3. Christy G, Tjandrawinata R R, Rachmawati H. Tabletting process of pellets containing bioactive fraction DLBS1033F isolated from lumbricus rubellus: Challenge and strategy. Biol Pharm Bull 2015; 38: 1843-1849. [DOI:10.1248/bpb.b15-00383]
4. Gayatri A, Nafrialdi N, Setiabudy R D, Tjandrawinata R R, Rachman A, Louisa M. A clinical trial on biological half life of bioactive protein from Lumbricus rubellus, DLBS1033 in healthy volunteers. Acta Med Indones 2018; 50: 208-214.
5. Hamel A, Roy M, Proudlock R. Chapter 4 - the bacterial reverse mutation test. In: Proudlock R, editor. Genetic toxicology testing. Boston: Academic Press, 2016, p. 79-138. [DOI:10.1016/B978-0-12-800764-8.00004-5]
6. ICH. S2(R1): Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. ICH; 2011.
7. Levy D D, Zeiger E, Escobar P A, Hakura A, B-JM v d L, Kato M, et al. Recommended criteria for the evaluation of bacterial mutagenicity data (Ames test). Mutation research/genetic toxicology and environmental. Mutagenesis 2019; 848: 403074. [DOI:10.1016/j.mrgentox.2019.07.004]
8. OECD. Test No. 471: bacterial reverse mutation test. OECD guidelines for the testing of chemicals, section 4. Paris: Organization for Economic Cooperation & Development; 1997.
9. Phillips D H, Arlt V M. Genotoxicity: damage to DNA and its consequences. EXS. 2009; 99: 87-110. [DOI:10.1007/978-3-7643-8336-7_4]
10. Pinzon R T, Tjandrawinata R R, Wijaya V O, Veronica V. Effect of DLBS1033 on functional outcomes for patients with acute ischemic stroke: A randomized controlled trial. Stroke Res Treat 2021; 2021: 5541616. [DOI:10.1155/2021/5541616]
11. Rong P, Zhang Z J, He R Q. Earthworm protease. Appl Environ Soil Sci 2010; 2010: 1-13. [DOI:10.1155/2010/294258]
12. Sommer S, Buraczewska I, Kruszewski M. Micronucleus assay: The state of art, and future directions. Int J Mol Sci 2020; 21:1534. [DOI:10.3390/ijms21041534]
13. Stephani L, Rahayu P, Retnoningrum D, Suhartono MT, Rachmawati H, Tjandrawinata RR. Purification and proteomic analysis of potent fibrinolytic enzymes extracted from Lumbricus rubellus. Proteome Sci. 2023;21(1):8. [DOI:10.1186/s12953-023-00206-9]
14. Sukandar E Y, Anggadireja K, Sigit J I, Adnyana I K, Tjandrawinata R R. Toxicity studies of a bioactive protein with antithrombotic-thrombolytic activity, DLBS1033. Drug Chem Toxicol 2014; 37: 8-16. [DOI:10.3109/01480545.2013.806526]
15. Tjandrawinata R R, Trisina J, Rahayu P, Prasetya L A, Hanafiah A, Rachmawati H. Bioactive protein fraction DLBS1033 containing lumbrokinase isolated from Lumbricus rubellus: ex vivo, in vivo, and pharmaceutic studies. Drug Des Devel Ther 2014; 8: 1585-1593. [DOI:10.2147/DDDT.S66007]
16. Tjandrawinata R R, stu Yunaidi D A, Susanto L W. The safety and tolerability of lumbrokinase DLBS1033 in healthy adult subjects. Drug Res (Stuttg) 2016; 66: 293-299. [DOI:10.1055/s-0035-1569406]
17. Trisina J, Sunardi F, Suhartono M T, Tjandrawinata R R. DLBS1033, a protein extract from Lumbricus rubellus, possesses antithrombotic and thrombolytic activities. J Biomed Biotechnol 2011; 2011: 519652. [DOI:10.1155/2011/519652]
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.